| Document |
Document Title |
|
WO/2010/127558A1 |
Substituted benzoyl urea compounds, preparation methods and pharmaceutical uses thereof are disclosed. The compounds are shown by general structure formula (I), wherein R1, R2 and R3 are defined as those in the description. The compounds...
|
|
WO/2010/128062A1 |
The invention relates to the use of O-imino-iso-urea compounds as source of radicals to polymerizable compositions comprising these O-imino-iso-urea and to new O-imino-iso-urea compounds. The O-lmino-isoureas compounds are compounds of t...
|
|
WO/2010/122968A1 |
Disclosed is a compound useful as an anti-obesity agent. Studies have been made on compounds which have a DGAT1 inhibitory activity and are therefore promising active ingredients for pharmaceutical compositions for treating obesity, type...
|
|
WO/2010/120138A2 |
The present invention relates to a salicylaldehyde chiral compound (chemical formula 1) and a naphtholaldehyde chiral compound (chemical formula 2), wherein a –OH group and a carbonyl group are adjacent to each other on a benzene ring....
|
|
WO/2010/113848A1 |
Disclosed is a compound represented by formula (I) or the like, which serves as an agent for treatment of diseases that are induced by production, secretion and/or deposition of amyloid β protein. Specifically disclosed is a compound re...
|
|
WO2010110555A2 |
The present invention relates to a method for obtaining optically pure amino acids, including optical resolution and optical conversion. The method of the present invention significantly shortens the time taken for optical transformation...
|
|
WO/2010/087318A1 |
Disclosed is a curable composition for a transfer material, which exhibits very good transferability in a nanoimprint process, while having a high selectivity between the dry etching rates by an argon gas and an oxygen gas. The curable c...
|
|
WO/2010/081683A1 |
The present invention provides compounds (n-3 PUFA derivatives) of formula (I) that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.
|
|
WO/2010/080795A2 |
Provided is a complex of hydrogen peroxide and at least one compound represented by Formula (I): wherein X is ( ), -C(R3)3, -C=C(R3), -O(R3), -N(R3)2, or -S(R3); and R1, R2, and R3 are each independently selected from H, alkyl, alkenyl, ...
|
|
WO/2010/075636A1 |
The present invention provides in part a compound of Formula (I) or a pharmaceutically- acceptable salt or stereoisomer thereof: where R1 is selected from the group consisting of a substituted triazole group, a guanidine group, a urea gr...
|
|
WO/2010/067005A1 |
The present invention relates to a method for preparing an allophanate, as well as to an allophanate and to a reduced viscosity polyisocyanate composition that contains the allophanate, intended for coating compositions, particularly pai...
|
|
WO/2010/065902A2 |
A compound of Formula (I), a pharmaceutically acceptable salt, or solvate thereof, complexes with metals such as rhenium, technetium, and others to provide a complex for imaging tissues or treating disease, particularly where the metal i...
|
|
WO/2010/063358A1 |
The invention relates to a method for producing a solution comprising urea urethanes and acting as a thixotropic agent, wherein at least two structurally different monohydroxy compounds are converted by an excess of toluylene diisocyanat...
|
|
WO/2010/062158A2 |
The present invention relates to the synthesis of lipophilic or immobilized monobasic phosphate (H2PO4) ionophores (7, 8a, 8b and 11) to be used as ion recognition molecules for monobasic phosphate (H2PO4") in the cocktail preparation of...
|
|
WO/2010/053128A1 |
Provided is a liquid crystal aligning agent capable of forming a liquid crystal alignment film the surface of which is rarely scratched or abraded when rubbed, and which exhibits excellent liquid crystal aligning properties and enables t...
|
|
WO/2010/046181A2 |
The invention relates to substances for defoaming aqueous media. Said substances contain urea derivatives of formula (I) in the form of solid particles as defoaming agents. In formula (I), R1 is a hydrocarbon group comprising 4 to 30 car...
|
|
WO/2010/035427A1 |
Disclosed is a urea compound represented by general formula (1). (In the formula, X1, X2 and X3 independently represent a hydrogen atom, an alkyl group or an aryl group. The aryl group may have one or more functional groups selected fro...
|
|
WO/2010/024298A1 |
Disclosed is a compound represented by formula (I) [wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the description] or a pharmaceutically acceptable salt or solvate thereof.
|
|
WO/2010/017470A1 |
The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composi...
|
|
WO/2010/017060A1 |
This invention relates to compounds of the Formula (I):or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which is useful for the treatment of diseases or conditions mediated by LpxC.
|
|
WO/2010/009508A1 |
A compound of Formula (A) wherein Z is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl, wherein the heteroaryl or substituted heteroaryl connected to a 2,4-dinito-6-(trifluoromethyl)phenyl ring via a carbon-carbon bond.
|
|
WO/2010/006085A1 |
The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprisi...
|
|
WO/2009/146539A1 |
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing 4-(aminome...
|
|
WO/2009/145989A2 |
Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described here...
|
|
WO/2009/132978A1 |
This invention relates to novel 4-dimethylaminobutyric acid derivatives of the formula (I) wherein A1, A2, R1, m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compo...
|
|
WO/2009/130422A2 |
The present invention relates to the use of acylthiourea or acylurea derivatives of formula (I) for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, an...
|
|
WO/2009/130317A1 |
The present invention relates to novel heterocyclic compounds which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the ...
|
|
WO/2009/121603A1 |
The invention relates to a method for producing at least one compound having at least one at least monosubstituted amino group. According to the invention, a starting substance supporting at least one amino group is reacted with an alcoh...
|
|
WO/2009/121607A1 |
The invention relates to a method for producing a compound having at least one at least monosubstituted amino group. According to the invention, a starting substance supporting at least one amino group is reacted with a reagent supportin...
|
|
WO/2009/124022A1 |
The invention provides amino- and amido-aminotetralin compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, and n are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opio...
|
|
WO/2009/121843A1 |
Process for increasing the capacity of an existing urea plant comprising a high-pressure urea synthesis section and one or more recovery sections, wherein next to the existing urea plant a urea production unit, comprising a high-pressure...
|
|
WO/2009/115491A1 |
The present invention relates to azolin-2-ylamino compounds of formulae (I) and (II), wherein n is 0 to 3; Ar is phenyl; A is a radical of formulae A1 or A2, wherein * indicates the point of attachment; X is S, O or N(R10); R7a-d are H, ...
|
|
WO/2009/117095A1 |
The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are...
|
|
WO/2009/115040A1 |
Benzoylurea compounds having the structure of formula (I) and uses thereof, wherein: R1 and R2 are independently selected from H, F, Cl, Br and I; R3, R4, R5, R6 and R7 are independently selected from H, halogen, C1-C6alkyl, C1-C6alkoxyl...
|
|
WO/2009/106351A1 |
The present invention provides a compound of formula (I): wherein: R1 is a group selected from -CH2OH1-NHCOH and R2 is a hydrogen atom; or R1 together with R2 form the group -NHC(O)CH=CH-, wherein the nitrogen atom is bound to the carbon...
|
|
WO/2009/096526A1 |
Provided is a compound having a CRTH2 antagonism and being useful as a preventive and/or remedy for inflammatory diseases (for example, asthma, allergic rhinitis, allergic dermatitis, conjunctivitis, urticaria, eosinophilic bronchitis, f...
|
|
WO/2009/096505A1 |
There have been required drugs, health foods and so on whereby subjective symptoms, for example, decline in clear thinking, defocusing and decline in memory of trivial matters can be reduced and the quality of life of people having these...
|
|
WO/2009/095164A1 |
The invention relates to a method for producing urethanes by the oxidative carbonylation of amino compounds in the presence of carbon monoxide, oxygen and organic compounds carrying hydroxyl groups, characterized in that the carbonylatio...
|
|
WO/2009/089192A1 |
The present invention provides novel phenoxyacetic acids useful for the prevention and treatment of inflammatory disorders, including those affecting the respiratory system and skin. The compounds are of the general formula (I):
|
|
WO/2009/089541A2 |
A method for designing a molecule capable of functioning as a PEPCK inhibitor can include identifying a molecule that has a size capable of fitting into and interacting with the PEPCK binding site and at least one of the following: (a) a...
|
|
WO/2009/086429A1 |
Disclosed are amide and urea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compo...
|
|
WO/2009/081892A1 |
Disclosed is a compound represented by the general formula (I) below which has a strong COMT inhibitory effect, or a pharmacologically acceptable salt thereof. Also disclosed are a pharmaceutical composition containing such a compound or...
|
|
WO/2009/071533A1 |
The present invention relates to novel polyisocyanates containing allophanate groups and based on isophorone diisocyanate and use thereof.
|
|
WO/2009/072798A1 |
A high adhesive acrylate monomer has a specific chemistry figure. This monomer may be easily prepared in a simplified way, and various linkers may be used between L-DOPA and an acrylate group attached to a tail of L-DOPA, so molecular we...
|
|
WO/2009/069132A2 |
Compounds that are capable of inhibiting an activity of a reverse transcriptase are disclosed. Further disclosed are pharmaceutical compositions containing these compounds, and methods of inhibiting an activity of reverse transcriptase a...
|
|
WO/2009/067597A1 |
Compounds of the formula: (I) are disclosed. The compounds act as phosphodiesterase-4 modulators, and useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions. Other embodiments are also disclosed.
|
|
WO/2009/063804A1 |
Disclosed is a process for producing N-carbamoyl-tert-leucine, which is characterized by mixing tert-leucine with an isocyanic acid compound in an amount of 0.9 to 1.1 times the amount of tert-leucine by mole, while keeping the pH value ...
|
|
WO/2009/053443A2 |
This invention provides new indane compounds, their use for the treatment or prevention of melatoninergic disorders and its compositions.
|
|
WO/2009/050041A1 |
The present invention relates to carbamoylglycine derivatives, a process for the preparation of carbamoylglycine derivatives and the use of carbamoylglycine derivatives in the preparation of enantiomerically enriched α-amino acids. Furt...
|
|
WO/2009/045830A1 |
This invention relates to a novel compound which is a glycogen phosphorylase inhibitor and its use in the treatment of diabetes and other conditions associated therewith. The invention further relates to a pharmaceutical composition cont...
|
